Adriano Gravina

2.3k total citations · 1 hit paper
53 papers, 958 citations indexed

About

Adriano Gravina is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Adriano Gravina has authored 53 papers receiving a total of 958 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 15 papers in Cancer Research. Recurrent topics in Adriano Gravina's work include Cancer Treatment and Pharmacology (14 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Treatments and Mutations (11 papers). Adriano Gravina is often cited by papers focused on Cancer Treatment and Pharmacology (14 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Treatments and Mutations (11 papers). Adriano Gravina collaborates with scholars based in Italy, United States and United Kingdom. Adriano Gravina's co-authors include Ana Oaknin, Anna V. Tinker, Susana Banerjee, Renaud Sabatier, G. Frasci, Lucy Gilbert, Cara Mathews, Cyril Abdeddaim, Víctor Moreno and Hadi Danaee and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Adriano Gravina

52 papers receiving 936 citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer

2020 237 citations Ana Oaknin, Anna V. Tinker et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Adriano Gravina Italy	16	591	317	193	171	166	53	958
Davide Lombardi Italy	17	609 1.0×	308 1.0×	210 1.1×	211 1.2×	57 0.3×	57	1.0k
Ida Paris Italy	16	370 0.6×	189 0.6×	210 1.1×	167 1.0×	98 0.6×	72	870
J. J. Kavanagh United States	17	396 0.7×	181 0.6×	308 1.6×	172 1.0×	232 1.4×	50	1.2k
Cristina Sonetto Italy	12	475 0.8×	160 0.5×	228 1.2×	213 1.2×	74 0.4×	22	781
Pierre‐Alexandre Just France	17	269 0.5×	281 0.9×	415 2.2×	222 1.3×	265 1.6×	45	1.1k
Gianni Amunni Italy	20	358 0.6×	224 0.7×	261 1.4×	175 1.0×	526 3.2×	55	1.2k
Russell Broaddus United States	13	218 0.4×	116 0.4×	228 1.2×	224 1.3×	103 0.6×	25	676
Saverio Danese Italy	16	408 0.7×	114 0.4×	228 1.2×	199 1.2×	102 0.6×	31	880
Svend A. Engelholm Denmark	17	262 0.4×	113 0.4×	177 0.9×	145 0.8×	97 0.6×	37	693
Eleni Timotheadou Greece	17	616 1.0×	222 0.7×	303 1.6×	201 1.2×	39 0.2×	76	1.0k

Countries citing papers authored by Adriano Gravina

Since Specialization

Citations

This map shows the geographic impact of Adriano Gravina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adriano Gravina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adriano Gravina more than expected).

Fields of papers citing papers by Adriano Gravina

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adriano Gravina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adriano Gravina. The network helps show where Adriano Gravina may publish in the future.

Co-authorship network of co-authors of Adriano Gravina

This figure shows the co-authorship network connecting the top 25 collaborators of Adriano Gravina. A scholar is included among the top collaborators of Adriano Gravina based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adriano Gravina. Adriano Gravina is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Arenare, Laura, Raimondo Di Liello, Pietro De Placido, et al.. (2024). Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials. ESMO Open. 9(3). 102941–102941. 3 indexed citations

Tinker, Anna V., Renaud Sabatier, Adriano Gravina, et al.. (2022). 2022-RA-1198-ESGO Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab. International Journal of Gynecological Cancer. 32. A414–A414. 5 indexed citations

Tinker, Anna V., Bhavana Pothuri, Renaud Sabatier, et al.. (2022). 548P Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study. Annals of Oncology. 33. S798–S799. 2 indexed citations

Oaknin, Ana, Anna V. Tinker, Lucy Gilbert, et al.. (2020). Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer. JAMA Oncology. 6(11). 1766–1766. 237 indexed citations breakdown →

Perrone, Francesco, Francesco Nuzzo, Francesca Di Rella, et al.. (2014). Weekly Docetaxel (Wd) Vs Cmf As Adjuvant Chemotherapy for Elderly Early Breast Cancer (Ebc) Patients (Pts): Final Results from the Randomised Phase 3 Elda Trial. Annals of Oncology. 25. iv86–iv86. 1 indexed citations

Nuzzo, Francesco, Federica Perrone, V. Labonia, et al.. (2007). 2034 POSTER Weekly docetaxel vs CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the ELDA trial. European Journal of Cancer Supplements. 5(4). 194–194. 1 indexed citations

Pacilio, Carmen, Alessandro Morabito, Francesco Nuzzo, et al.. (2006). Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. British Journal of Cancer. 94(9). 1233–1236. 21 indexed citations

Daponte, Antonio, Paolo A. Ascierto, Adriano Gravina, et al.. (2005). Temozolomide and cisplatin in avdanced malignant melanoma.. PubMed. 25(2B). 1441–7. 14 indexed citations

Ardizzoni, Andrea, Giovanna Antonelli, Sante Basso Ricci, et al.. (2000). Ambamustine in the Second-Line Treatment of Patients With Small-Cell Lung Cancer. American Journal of Clinical Oncology. 23(1). 22–25. 7 indexed citations

10.

Daponte, Antonio, Paolo A. Ascierto, Adriano Gravina, et al.. (2000). Cisplatin, dacarbazine, and fotemustine plus interferon α in patients with advanced malignant melanoma. Cancer. 89(12). 2630–2636.

11.

Iaffaioli, Rosario Vincenzo, Adriano Gravina, Gaetano Facchini, et al.. (2000). Phase I–II study of gemcitabine and paclitaxel in pretreated patients with stage IIIB–IV non-small cell lung cancer. Lung Cancer. 30(3). 203–210. 10 indexed citations

12.

Caponigro, Francesco, Pasquale Comella, Maria Biglietto, et al.. (1999). A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5‐fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck. Cancer. 85(4). 952–959. 1 indexed citations

13.

Caponigro, Francesco, Pasquale Comella, Maria Biglietto, et al.. (1999). A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck. Cancer. 85(4). 952–959. 8 indexed citations

14.

Comella, P., Antonio Daponte, Rossana Casaretti, et al.. (1997). Fotemustine and dacarbazine plus recombinant interferon alpha2a in the treatment of advanced melanoma. European Journal of Cancer. 33(8). 1326–1329. 10 indexed citations

15.

Frasci, G., P. Comella, Cesare Guida, et al.. (1997). Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.. Journal of Clinical Oncology. 15(4). 1409–1417. 23 indexed citations

16.

Iaffaioli, Rosario Vincenzo, Gaetano Facchini, Francesco Caponigro, et al.. (1997). Phase I study of vinorelbine and paclitaxel in small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 41(1). 86–90. 6 indexed citations

17.

Wang, Hui, Simone Maurea, Ciro Gabriele Mainolfi, et al.. (1997). Tc-99m MIBI Scintigraphy in Patients With Lung Cancer Comparison with CT and Fluorine-18 FDG PET Imaging. Clinical Nuclear Medicine. 22(4). 243–249. 21 indexed citations

18.

Comella, Pasquale, Giuseppe Palmieri, Gerardo Beneduce, et al.. (1996). Significance of Methotrexate Serum Level Achieved in Patients with Gastrointestinal Malignancies Treated with Sequential Methotrexate, <i>L</i>-Folinic Acid and 5-Fluorouracil. Oncology. 53(3). 198–203. 4 indexed citations

19.

Palmieri, Giuseppe, et al.. (1996). Thymostimulin treatment of hepatocellular carcinoma on liver cirrhosis. International Journal of Oncology. 8(4). 827–32. 9 indexed citations

20.

Perrone, Francesco, Sabino De Placido, Chiara Carlomagno, et al.. (1994). Mitomycin C and Mitoxantrone in Anthracycline-Pretreated Advanced Breast Cancer Patients. American Journal of Clinical Oncology. 17(3). 218–222. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact